What are the clinical differences between acute colonic pseudo-obstruction (ACPO) and toxic megacolon?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clinical Differences Between Acute Colonic Pseudo-Obstruction (ACPO) and Toxic Megacolon

The primary difference between ACPO and toxic megacolon is that ACPO is a non-inflammatory colonic dilatation occurring in patients with severe underlying medical conditions, while toxic megacolon is an inflammatory colonic dilatation with systemic toxicity typically associated with underlying inflammatory bowel disease or infectious colitis. 1, 2, 3

Etiology and Pathophysiology

ACPO (Ogilvie's Syndrome)

  • Non-inflammatory, functional colonic dilatation
  • Occurs in patients with severe medical or surgical conditions
  • Attributed to sympathetically mediated reflex response
  • No mechanical obstruction present
  • Develops over several days
  • Motility disorder without underlying colonic inflammation 2, 3

Toxic Megacolon

  • Inflammatory colonic dilatation
  • Associated with underlying inflammatory bowel disease (IBD) or infectious colitis (especially C. difficile)
  • Caused by severe transmural inflammation of the colon
  • Characterized by systemic toxicity
  • Can develop rapidly
  • Involves severe inflammation of the colonic wall 1, 4

Clinical Presentation

ACPO

  • Abdominal distention
  • Abdominal pain
  • Nausea and vomiting
  • Absence of diarrhea (often constipation or ileus)
  • No signs of systemic toxicity
  • Occurs in hospitalized patients with serious underlying medical/surgical conditions 2, 5

Toxic Megacolon

  • Abdominal distention
  • Abdominal pain
  • Diarrhea (often bloody)
  • Fever (core body temperature >38.5°C)
  • Tachycardia
  • Hypotension/hemodynamic instability
  • Rigors
  • Signs of peritonitis
  • Systemic toxicity 4, 1

Laboratory Findings

ACPO

  • Usually no marked leukocytosis
  • No significant elevation in inflammatory markers
  • Electrolyte abnormalities may be present 2

Toxic Megacolon

  • Marked leukocytosis (>15 × 10⁹/L)
  • Left shift (band neutrophils >20% of leukocytes)
  • Elevated inflammatory markers
  • Rise in serum creatinine (>50% above baseline)
  • Elevated serum lactate
  • Hypoalbuminemia (<25 g/L) 4, 1

Radiological Findings

ACPO

  • Colonic dilatation (cecal diameter ≥12 cm)
  • No evidence of mechanical obstruction
  • Absence of colonic wall thickening
  • No pericolonic fat stranding 2, 6

Toxic Megacolon

  • Colonic dilatation (transverse colon >5.5 cm)
  • Colonic wall thickening
  • Pericolonic fat stranding
  • Ascites not explained by other causes
  • Haustral or mucosal thickening
  • Thumbprinting, pseudopolyps, and plaques may be present 4, 1

Endoscopic Findings

ACPO

  • Normal colonic mucosa or mild non-specific changes
  • No evidence of inflammation
  • No pseudomembranes 2

Toxic Megacolon

  • Pseudomembranous colitis (in C. difficile cases)
  • Severe mucosal inflammation
  • Ulcerations
  • Friability
  • Edema and erythema 4, 1

Complications

ACPO

  • Ischemia (when cecal diameter exceeds 12 cm)
  • Perforation (risk increases with cecal diameter >12 cm and distention >6 days)
  • 25-30% overall mortality, increasing to 50% with complications 2, 7

Toxic Megacolon

  • Perforation (27-57% mortality rate)
  • Massive hemorrhage
  • Septic shock
  • Multi-organ failure
  • Higher mortality rate compared to ACPO, especially with perforation 1

Management Approach

ACPO

  • Supportive care (IV fluids, electrolyte correction)
  • Discontinue medications that decrease gut motility
  • Neostigmine (first-line pharmacological therapy)
  • Endoscopic decompression if no response to neostigmine
  • Surgery only if complications develop 2, 7, 3

Toxic Megacolon

  • Bowel rest
  • Aggressive IV fluid resuscitation
  • Parenteral corticosteroids (for IBD-related cases)
  • Broad-spectrum antibiotics
  • Empirical oral vancomycin (for suspected C. difficile)
  • Close monitoring with daily assessment
  • Early surgical consultation
  • Lower threshold for surgical intervention 4, 1

Key Diagnostic Distinctions

  • ACPO must be differentiated from mechanical obstruction using water-soluble contrast enema or CT
  • Toxic megacolon requires identification of underlying inflammatory or infectious cause (IBD, C. difficile)
  • Plain abdominal radiograph is acceptable as first study to detect toxic megacolon 4
  • CT is preferred for ACPO diagnosis and to rule out complications 2

Understanding these differences is crucial for proper management and to reduce the significant morbidity and mortality associated with both conditions.

References

Guideline

Diagnosis and Management of Toxic Megacolon

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Acute colonic pseudo-obstruction: Ogilvie syndrome].

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2015

Research

Acute and chronic megacolon.

Current treatment options in gastroenterology, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Megacolon: Acute, Toxic, and Chronic.

Current treatment options in gastroenterology, 1999

Research

Acute colonic pseudo-obstruction.

Best practice & research. Clinical gastroenterology, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.